Cargando…
Diverting Ileostomy Duration Is the Main Determinant of Ileostomy-Related Complications after Surgical Treatment of Rectum Cancer
BACKGROUND: This study aimed to investigate factors associated with the development of ileostomy complications in rectal cancer patients, including those who received neoadjuvant treatment. METHODS: This retrospective trial included 133 consecutive patients who underwent surgery for rectal cancer wi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166299/ https://www.ncbi.nlm.nih.gov/pubmed/32322269 http://dx.doi.org/10.1155/2020/4186857 |
_version_ | 1783523531799134208 |
---|---|
author | Hacim, Nadir Adnan Akbas, Ahmet Meric, Serhat Altinel, Yüksel Karabay, Onder Yavuz, Erkan |
author_facet | Hacim, Nadir Adnan Akbas, Ahmet Meric, Serhat Altinel, Yüksel Karabay, Onder Yavuz, Erkan |
author_sort | Hacim, Nadir Adnan |
collection | PubMed |
description | BACKGROUND: This study aimed to investigate factors associated with the development of ileostomy complications in rectal cancer patients, including those who received neoadjuvant treatment. METHODS: This retrospective trial included 133 consecutive patients who underwent surgery for rectal cancer with temporary diverting ileostomy. Patients' demographic characteristics as well as the pre- and postclosure outcomes and complications were analyzed. RESULTS: In logistic regression analysis, longer duration of ileostomy emerged as a significant independent predictor of any complication during ileostomy. The respective odds ratios for 3–6 months and >6 months vs. <3 months of ileostomy duration were as follows: OR, 4.5 (95% CI, 1.2–16.7), p=0.023; and OR, 15.2 (95% CI, 3.1–75.2), p=0.001. An additional stepwise model also identified hypertension as a significant predictor. In stepwise logistic regression model, adjuvant chemoradiotherapy emerged as significant independent predictor of “any ileostomy-related complication after ileostomy closure”: OR, 4.5 (2.0–10.2), p < 0.001. CONCLUSION: Duration of ileostomy appears to be the main determinant of ileostomy-related complications. Patients who had received neoadjuvant or adjuvant therapy had longer ileostomy duration, which may be attributed to the concerns of the surgeon or to the complications themselves. |
format | Online Article Text |
id | pubmed-7166299 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-71662992020-04-22 Diverting Ileostomy Duration Is the Main Determinant of Ileostomy-Related Complications after Surgical Treatment of Rectum Cancer Hacim, Nadir Adnan Akbas, Ahmet Meric, Serhat Altinel, Yüksel Karabay, Onder Yavuz, Erkan J Oncol Research Article BACKGROUND: This study aimed to investigate factors associated with the development of ileostomy complications in rectal cancer patients, including those who received neoadjuvant treatment. METHODS: This retrospective trial included 133 consecutive patients who underwent surgery for rectal cancer with temporary diverting ileostomy. Patients' demographic characteristics as well as the pre- and postclosure outcomes and complications were analyzed. RESULTS: In logistic regression analysis, longer duration of ileostomy emerged as a significant independent predictor of any complication during ileostomy. The respective odds ratios for 3–6 months and >6 months vs. <3 months of ileostomy duration were as follows: OR, 4.5 (95% CI, 1.2–16.7), p=0.023; and OR, 15.2 (95% CI, 3.1–75.2), p=0.001. An additional stepwise model also identified hypertension as a significant predictor. In stepwise logistic regression model, adjuvant chemoradiotherapy emerged as significant independent predictor of “any ileostomy-related complication after ileostomy closure”: OR, 4.5 (2.0–10.2), p < 0.001. CONCLUSION: Duration of ileostomy appears to be the main determinant of ileostomy-related complications. Patients who had received neoadjuvant or adjuvant therapy had longer ileostomy duration, which may be attributed to the concerns of the surgeon or to the complications themselves. Hindawi 2020-04-07 /pmc/articles/PMC7166299/ /pubmed/32322269 http://dx.doi.org/10.1155/2020/4186857 Text en Copyright © 2020 Nadir Adnan Hacim et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Hacim, Nadir Adnan Akbas, Ahmet Meric, Serhat Altinel, Yüksel Karabay, Onder Yavuz, Erkan Diverting Ileostomy Duration Is the Main Determinant of Ileostomy-Related Complications after Surgical Treatment of Rectum Cancer |
title | Diverting Ileostomy Duration Is the Main Determinant of Ileostomy-Related Complications after Surgical Treatment of Rectum Cancer |
title_full | Diverting Ileostomy Duration Is the Main Determinant of Ileostomy-Related Complications after Surgical Treatment of Rectum Cancer |
title_fullStr | Diverting Ileostomy Duration Is the Main Determinant of Ileostomy-Related Complications after Surgical Treatment of Rectum Cancer |
title_full_unstemmed | Diverting Ileostomy Duration Is the Main Determinant of Ileostomy-Related Complications after Surgical Treatment of Rectum Cancer |
title_short | Diverting Ileostomy Duration Is the Main Determinant of Ileostomy-Related Complications after Surgical Treatment of Rectum Cancer |
title_sort | diverting ileostomy duration is the main determinant of ileostomy-related complications after surgical treatment of rectum cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166299/ https://www.ncbi.nlm.nih.gov/pubmed/32322269 http://dx.doi.org/10.1155/2020/4186857 |
work_keys_str_mv | AT hacimnadiradnan divertingileostomydurationisthemaindeterminantofileostomyrelatedcomplicationsaftersurgicaltreatmentofrectumcancer AT akbasahmet divertingileostomydurationisthemaindeterminantofileostomyrelatedcomplicationsaftersurgicaltreatmentofrectumcancer AT mericserhat divertingileostomydurationisthemaindeterminantofileostomyrelatedcomplicationsaftersurgicaltreatmentofrectumcancer AT altinelyuksel divertingileostomydurationisthemaindeterminantofileostomyrelatedcomplicationsaftersurgicaltreatmentofrectumcancer AT karabayonder divertingileostomydurationisthemaindeterminantofileostomyrelatedcomplicationsaftersurgicaltreatmentofrectumcancer AT yavuzerkan divertingileostomydurationisthemaindeterminantofileostomyrelatedcomplicationsaftersurgicaltreatmentofrectumcancer |